Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. Fundamental Analysis
Neuphoria Therapeutics Inc. (NEUP) shows moderate financial fundamentals with a PE ratio of -0.07, profit margin of 25.01%, and ROE of -15.59%. The company generates $-0.0B in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -1499.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze NEUP's fundamental strength across five key dimensions:
Efficiency Score
WeakNEUP struggles to generate sufficient returns from assets.
Valuation Score
ExcellentNEUP trades at attractive valuation levels.
Growth Score
ModerateNEUP shows steady but slowing expansion.
Financial Health Score
ExcellentNEUP maintains a strong and stable balance sheet.
Profitability Score
ModerateNEUP maintains healthy but balanced margins.
Key Financial Metrics
Is NEUP Expensive or Cheap?
P/E Ratio
NEUP trades at -0.07 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NEUP's PEG of -0.00 indicates potential undervaluation.
Price to Book
The market values Neuphoria Therapeutics Inc. at 0.89 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.05 times EBITDA. This is generally considered low.
How Well Does NEUP Make Money?
Net Profit Margin
For every $100 in sales, Neuphoria Therapeutics Inc. keeps $25.01 as profit after all expenses.
Operating Margin
Core operations generate 73.19 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-15.59 in profit for every $100 of shareholder equity.
ROA
Neuphoria Therapeutics Inc. generates $-11.25 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Neuphoria Therapeutics Inc. generates limited operating cash flow of $59.77M, signaling weaker underlying cash strength.
Free Cash Flow
Neuphoria Therapeutics Inc. generates weak or negative free cash flow of $59.77M, restricting financial flexibility.
FCF Per Share
Each share generates $11.09 in free cash annually.
FCF Yield
NEUP converts 2.25% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.07
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.89
vs 25 benchmark
P/S Ratio
Price to sales ratio
-1.67
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
14.31
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-15.59
vs 25 benchmark
ROA
Return on assets percentage
-11.25
vs 25 benchmark
ROCE
Return on capital employed
-34.43
vs 25 benchmark
How NEUP Stacks Against Its Sector Peers
| Metric | NEUP Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.07 | 28.62 | Better (Cheaper) |
| ROE | -1559.18% | 788.00% | Weak |
| Net Margin | 2501.32% | -48085.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 14.31 | 4.11 | Strong Liquidity |
| ROA | -1125.49% | -21875.00% (disorted) | Weak |
NEUP outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Neuphoria Therapeutics Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-100.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
33.65%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
60.99%
Industry Style: Defensive, Growth, Innovation
High Growth